

Achievement by Micromedic, BioLight's Cancer Diagnostic Cluster:

Marketing approval for ZetiQ's CellDetect® in China, for diagnosing cervical cancer cells.

The Chinese market has the potential for millions of screening tests to detect cervical cancer

Tel Aviv, Israel, November 20, 2012: Micromedic (TASE: MCTC), a development and commercialization company working to create value through a cluster of cancer diagnostics companies, and **BioLight Investments (TASE: BOLT)**, which spearheads unique strategies to encourage innovation in the life sciences, have announced that the product CellDetect®, manufactured by ZetiQ – a subsidiary under the full control of Micromedic, designed to diagnose cancerous cells in the cervix, has been approved by the State Food and Drug Administration (SFDA) of the People's Republic of China for marketing in China.

Suzana Nahum-Zilberberg, CEO of BioLight and a director of Micromedic: "Receiving authorization to market in China is an example of BioLight's ability to implement its cluster strategy, and bears substantial importance for Micromedic's applied cluster strategy revolving around cancer diagnostics. Achieving this milestone propels Micromedic into a projected start of sales in China in 2013, enabling it to promote additional projects in the same field in the long run while generating immediate value for company shareholders."

Dr. Adi Elkeles, CTO and CBDO of the cluster, and former ZetiQ CEO: "We are thrilled to have received authorization to market ZetiQ's CellDetect® in China. The approval constitutes a significant step for ZetiQ and further confirmation of the existing potential in the CellDetect® technology. It allows the company to get a first foot in the door of the Chinese market, where there is a real need for a reliable, inexpensive product that will make it easier for the government to urge the population to screen for early detection of cervical cancer and thereby decrease the number of deaths from the disease.

"Our Chinese partner has designated marketing of the kit to the government sector as well as the private sector, markets with the potential for millions of cervical cancer screening tests. Receiving approval means we have passed a major milestone in ZetiQ's contract with Biomics as we approach the phase of starting to make sales."

About BioLight:

BioLight Israeli Life Sciences Investments Ltd. is a holding and management company that works through subsidiaries to establish and manage clusters of companies in defined fields, while investing in companies engaging in the research and development of pharmaceuticals and medical products. The company was founded in April 2005, and in April 2011 a group of investors headed by Mr. Israel Makov acquired control over the company and initiated a new strategy of creating value through sharing information (the cluster approach).

BioLight functions according to a unique business cluster model based on creating value through synergies stemming from information-sharing among companies handling common and tangential fields. The model is based on a combination of activities dealing with one disease from various angles: medicines, medical instruments, molecular diagnosis, imaging and more, all under a defined cluster of companies. Such cooperation can create added value by forming a base of knowledge and experience that provides comprehensive familiarity with the disease, the market, the competition and the leading parties in the field, producing unique, cutting-edge solutions and proving more effective for signing cooperation agreements with leading strategic partners.

For further information please visit www.bio-light.co.il

About Micromedic:

Micromedic engages in research, development, investments and commercialization; and manages a cluster of companies in the field of cancer disease diagnostics, by developing and commercializing biomarkers based on various molecules and genes, among other methods, doing so mainly through its subsidiaries. Micromedic is a publicly-traded company, with BioLight holding 25.45% of Micromedic's issued and paid up capital. Micromedic holds 100% of Zetiq's capital.

For further information please visit www.m-medic.com

About Zetiq:

Zetiq develops products to detect and diagnose cancer, based on the company's exclusive CellDetect® technology, enabling diagnosis by differential staining along with morphological detection of cancerous and precancerous cells. CellDetect® technology allows identifying cancerous cells that appear in low frequency even among a very large population of noncancerous cells. It also allows diagnosing different kinds of cancer. These special qualities make it possible to develop a wide range of products based on the technology for diagnosing different kinds of cancer and various applications in pathological diagnosis. The designated competitive price of the company products and the advantages of using them increase the potential for wide penetration of the pathological diagnostics market.

The basket of company products will be directed at the pathological anatomy market, a market estimated at over 13 billion dollars. Zetiq has proven the feasibility of early detection of cervical cancer cells and identification of cancerous cells in the urinary bladder, and is advancing the company's plans to develop tools to diagnose these diseases.

For further information please visit www.zetiq.co.il

About Biomics Biotechnologies Co.:

The Chinese company specializes in developing and distributing medicines, and in iRNA technology. It sells a range of products in the realms of molecular biology and diagnostics.

